inclusion criteria: 1. adults of either gender aged 18 to 65 years inclusive. 2. patients within 4-12 weeks of the confirmed covid-19 onset . 3. symptoms of asthenia that appeared during or after an acute new coronavirus infection (covid-19), persisting from 4 to 12 weeks from the onset of coronavirus infection. 4. presence of asthenia (≥36 on the fss scale). 5. patients who agreed to use a reliable method of contraception during the study (for men and women with reproductive potential). 6. presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: 1. adults of either gender aged 18 to 65 years inclusive. 2. patients within 4-12 weeks of the confirmed covid-19 onset . 3. symptoms of asthenia that appeared during or after an acute new coronavirus infection (covid-19), persisting from 4 to 12 weeks from the onset of coronavirus infection. 4. presence of asthenia (≥36 on the fss scale). 5. patients who agreed to use a reliable method of contraception during the study (for men and women with reproductive potential). 6. presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: adults of either gender aged 18 to 65 years inclusive. patients within 4-12 weeks of the confirmed covid-19 onset . symptoms of asthenia that appeared during or after an acute new coronavirus infection (covid-19), persisting from 4 to 12 weeks from the onset of coronavirus infection. presence of asthenia (≥36 on the fss scale). patients who agreed to use a reliable method of contraception during the study (for men and women with reproductive potential). presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: adults of either gender aged 18 to 65 years inclusive. patients within 4-12 weeks of the confirmed covid-19 onset . symptoms of asthenia that appeared during or after an acute new coronavirus infection (covid-19), persisting from 4 to 12 weeks from the onset of coronavirus infection. presence of asthenia (≥36 on the fss scale). patients who agreed to use a reliable method of contraception during the study (for men and women with reproductive potential). presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: 1. adults of either gender aged 18 to 65 years inclusive. 2. patients within 4-12 weeks of the confirmed covid-19 onset . 3. symptoms of asthenia that appeared during or after an acute new coronavirus infection (covid-19), persisting from 4 to 12 weeks from the onset of coronavirus infection. 4. presence of asthenia (≥36 on the fss scale). 5. patients who agreed to use a reliable method of contraception during the study (for men and women with reproductive potential). 6. presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: 1. adults of either gender aged 18 to 65 years inclusive. 2. patients within 4-12 weeks of the confirmed covid-19 onset . 3. symptoms of asthenia that appeared during or after an acute new coronavirus infection (covid-19), persisting from 4 to 12 weeks from the onset of coronavirus infection. 4. presence of asthenia (≥36 on the fss scale). 5. patients who agreed to use a reliable method of contraception during the study (for men and women with reproductive potential). 6. presence of a signed information sheet and informed consent form for participation in a clinical trial.